PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform(PRFX) GlobeNewswire News Room·2024-09-11 20:30
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess the impact of PR ...